相关实验视频

Updated: May 14, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

奥西默提尼布:在EGFR驱动肺癌第四阶段的游戏改变者

Sofia Silva¹, Joana Duarte¹, Carla Simão¹

¹Pulmonology Department. Hospital Beatriz Ângelo. Unidade Local de Saúde Loures-Odivelas. Lisboa. Portugal.

Acta medica portuguesa

|April 11, 2025

概括

一名患有晚期非小细胞肺癌 (NSCLC) 的患者对针对EGFR突变的向治疗 - - 奥西默蒂尼布 (osimertinib) 产生了完全反应. 这一案例突显了EGFR抑制剂在晚期NSCLC中的有效性.

科学领域:

在瘤学瘤学.
肺部病理学肺部病理学
药理学药理学是指药理学的学科.

背景情况:

晚期非小细胞肺癌 (NSCLC) 的死亡率很高,但有针对性的疗法改善了生存率.
表皮生长因子受体 (EGFR) 突变发生在约15%的NSCLC病例中.
奥西默提尼布是一种EGFR氨酸激酶抑制剂,已被批准用于先进NSCLC与EGFR敏感突变的第一线治疗.

研究的目的:

报告一个先进的NSCLC病例,EGFR外基因19缺失,用一线 osimertinib 治疗.
要突出在患有广泛转移性疾病的患者中实现完整的代谢反应和显著的临床改善.

主要方法:

一名55岁的男性前吸烟者,有六个月的咳和呼吸障碍病史,被诊断患有肺腺癌.
通过支气管活检证实了诊断,该活检显示EGFR外基因19的缺失.
阶段检测显示了IV-A阶段的肺和上腺转移的疾病;治疗开始使用一线 osimertinib.

主要成果:

患者在开始服用 osimertinib.com 五个月后,在 PET-CT 上获得了完全的代谢反应.
观察到显著的临床改善,患者恢复了体力活动,并实现了0.0的性能状态.
尽管有广泛的胸部疾病,但 osimertinib 在这个患者中表现出高效.

结论:

在患有晚期NSCLC和EGFR突变的患者中,奥西默提尼布可以诱导显著的反应,包括完整的代谢反应.
这一案例强调了EGFR氨酸激酶抑制剂的疗效,但也提出了关于治疗持续时间和监测的问题.
需要进一步研究以了解影响罕见完整反应的因素以及循环瘤DNA的作用.

关键词:

癌瘤的癌症是什么在ErbB受体中.肺部新生体/药物治疗非小细胞肺/药物治疗奥西默蒂尼布 (Osimertinib) 是一种药物.

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...